Sirona Biochem (TSE:SBM) has released an update.
Sirona Biochem’s GlycoProteMim has been recognized in Stonegate Healthcare’s report as a notable innovation in the $12.5 billion anti-aging skincare market. The ingredient stands out for its dual action on surface-level appearance and cellular mechanisms, offering a potentially safer and non-invasive alternative to traditional treatments like Botox and dermal fillers. Sirona Biochem is poised to launch GlycoProteMim through Sirona Laboratories in Europe and North America in early 2025.
For further insights into TSE:SBM stock, check out TipRanks’ Stock Analysis page.
